Sino Biopharmaceutical reports strong profit, revenue growth in H1 2025

Sino Biopharmaceutical Limited announced a 10.7% year-on-year increase in revenue, reaching RMB17,574.78 million for the six months ended June 30, 2025. Profit attributable to owners of the parent from continuing operations surged by 140.2% to RMB3,388.59 million. The underlying profit, a non-HKFRS measure, also saw a substantial rise of 101.1% to RMB3,087.65 million. Basic earnings per share from continuing operations were RMB18.82 cents, up 145.7% from the previous year.

The company's innovative products were a key growth driver, with sales totaling RMB7,798.57 million, an increase of 27.2% year-on-year, and contributing 44.4% to total revenue. Oncology medicines sales grew by 24.9% to RMB6,694.23 million, while surgery/analgesia medicines sales increased by 20.2% to RMB3,105.06 million. R&D costs amounted to RMB3,187.56 million, representing 18.1% of the Group's revenue.

Strategic activities included the full acquisition of LaNova Medicines in July 2025 for a net consideration of US$500 million, aiming to enhance oncology innovation. The company also declared an interim dividend of HK5 cents per share for the period.